Media Summary: The study by Marin et al is another milestone in our understanding how to manage Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, ... The Philadelphia chromosome, which is found in leukemic cells in more than 90% of all patients

Using Bcr Abl Transcript Levels - Detailed Analysis & Overview

The study by Marin et al is another milestone in our understanding how to manage Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, ... The Philadelphia chromosome, which is found in leukemic cells in more than 90% of all patients Javier Pinilla-Ibarz, MD, PhD, and Camille N. Abboud, MD, discuss the possibility of combining omacetaxine Treatment-free remission is the goal in chronic myeloid leukemia ( Harry P. Erba, MD; Michael Mauro, MD; and Jorge E. Cortes, MD, share insight into what factors they consider when selecting a ...

Reynaldo Garcia, RN, OCN® from the University of North Carolina Lineberger Comprehensive Cancer Center Explains the ... Qin et al. "Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused ... Javier Pinilla-Ibarz, MD, PhD, and Camille N. Abboud, MD, discuss the milestones for The Philadelphia chromosome or Philadelphia translocation (Ph) is a specific genetic abnormality in chromosome 22 of leukemia ... Jorge E. Cortes, MD; Harry P. Erba, MD; and Michael Mauro, MD, consider the optimal management of Harry P. Erba, MD; Jorge E. Cortes, MD; and Michael Mauro, MD, reflect on the value of having 4

Photo Gallery

Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict ...
Dr. Erba Discusses the Failure to Achieve a BCR-ABL Transcript Level Below 10% After Imatinib in CML
BCR-ABL1 and the Philadelphia chromosome - Part 2: The Philadelphia chromosome
Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML
Evaluation of BCR-ABL monitoring in Chronic Myelogenous Leukemia in clinical practice
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
CML: Factors in Selecting a BCR-ABL TKI
Reynaldo Garcia Explains the BCR-ABL Study
Researchers identify a key molecular pathway in Philadelphia-positive acute lymphoblastic leukemia
Defining Suboptimal Response to BCR-ABL TKI Therapy in CML
bcr-abl Translocation  Mechanism | Philadelphia Chromosome
Optimizing the Use of BCR-ABL TKIs in CML
View Detailed Profile
Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict ...

Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict ...

The study by Marin et al is another milestone in our understanding how to manage

Dr. Erba Discusses the Failure to Achieve a BCR-ABL Transcript Level Below 10% After Imatinib in CML

Dr. Erba Discusses the Failure to Achieve a BCR-ABL Transcript Level Below 10% After Imatinib in CML

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, ...

BCR-ABL1 and the Philadelphia chromosome - Part 2: The Philadelphia chromosome

BCR-ABL1 and the Philadelphia chromosome - Part 2: The Philadelphia chromosome

The Philadelphia chromosome, which is found in leukemic cells in more than 90% of all patients

Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML

Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML

Javier Pinilla-Ibarz, MD, PhD, and Camille N. Abboud, MD, discuss the possibility of combining omacetaxine

Evaluation of BCR-ABL monitoring in Chronic Myelogenous Leukemia in clinical practice

Evaluation of BCR-ABL monitoring in Chronic Myelogenous Leukemia in clinical practice

From ONS 2011 - A discussion

Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts

Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts

Treatment-free remission is the goal in chronic myeloid leukemia (

CML: Factors in Selecting a BCR-ABL TKI

CML: Factors in Selecting a BCR-ABL TKI

Harry P. Erba, MD; Michael Mauro, MD; and Jorge E. Cortes, MD, share insight into what factors they consider when selecting a ...

Reynaldo Garcia Explains the BCR-ABL Study

Reynaldo Garcia Explains the BCR-ABL Study

Reynaldo Garcia, RN, OCN® from the University of North Carolina Lineberger Comprehensive Cancer Center Explains the ...

Researchers identify a key molecular pathway in Philadelphia-positive acute lymphoblastic leukemia

Researchers identify a key molecular pathway in Philadelphia-positive acute lymphoblastic leukemia

Qin et al. "Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused ...

Defining Suboptimal Response to BCR-ABL TKI Therapy in CML

Defining Suboptimal Response to BCR-ABL TKI Therapy in CML

Javier Pinilla-Ibarz, MD, PhD, and Camille N. Abboud, MD, discuss the milestones for

bcr-abl Translocation  Mechanism | Philadelphia Chromosome

bcr-abl Translocation Mechanism | Philadelphia Chromosome

The Philadelphia chromosome or Philadelphia translocation (Ph) is a specific genetic abnormality in chromosome 22 of leukemia ...

Optimizing the Use of BCR-ABL TKIs in CML

Optimizing the Use of BCR-ABL TKIs in CML

Jorge E. Cortes, MD; Harry P. Erba, MD; and Michael Mauro, MD, consider the optimal management of

CML: Frontline BCR-ABL TKI Therapy

CML: Frontline BCR-ABL TKI Therapy

Harry P. Erba, MD; Jorge E. Cortes, MD; and Michael Mauro, MD, reflect on the value of having 4